|
1
|
Li Z, Yu X, Shen J, Law PT, Chan MT and Wu
WK: MicroRNA expression and its implications for diagnosis and
therapy of gallbladder cancer. Oncotarget. 6:13914–13921.
2015.PubMed/NCBI
|
|
2
|
Subbannayya T, Leal-Rojas P, Barbhuiya MA,
Raja R, Renuse S, Sathe G, Pinto SM, Syed N, Nanjappa V, Patil AH,
et al: Macrophage migration inhibitory factor - a therapeutic
target in gallbladder cancer. BMC Cancer. 15:8432015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shu YJ, Bao RF, Jiang L, Wang Z, Wang XA,
Zhang F, Liang HB, Li HF, Ye YY, Xiang SS, et al: MicroRNA-29c-5p
suppresses gallbladder carcinoma progression by directly targeting
CPEB4 and inhibiting the MAPK pathway. Cell Death Differ.
24:445–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: SPOCK1 as a potential
cancer prognostic marker promotes the proliferation and metastasis
of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol
Cancer. 14:122015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagaraja V and Eslick GD: Systematic
review with meta-analysis: The relationship between chronic
Salmonella typhi carrier status and gall-bladder cancer.
Aliment Pharmacol Ther. 39:745–750. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carriaga MT and Henson DE: Liver,
gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 75
Suppl 1:S171–S190. 1995. View Article : Google Scholar
|
|
7
|
Jung W, Jang JY, Kang MJ, Chang YR, Shin
YC, Chang J and Kim SW: Effects of surgical methods and tumor
location on survival and recurrence patterns after curative
resection in patients with T2 gallbladder cancer. Gut Liver.
10:140–146. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z,
Liu C, Shen B, Wang XA, Wu W, et al: Whole-exome and targeted gene
sequencing of gallbladder carcinoma identifies recurrent mutations
in the ErbB pathway. Nat Genet. 46:872–876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao S, Cao Y, Liu SB, Wang XA, Bao RF,
Shu YJ, Hu YP, Zhang YJ, Jiang L, Zhang F, et al: The E545K
mutation of PIK3CA promotes gallbladder carcinoma progression
through enhanced binding to EGFR. JJ Exp Clin Cancer Res.
35:972016. View Article : Google Scholar
|
|
10
|
Marcano-Bonilla L, Mohamed EA, Mounajjed T
and Roberts LR: Biliary tract cancers: Epidemiology, molecular
pathogenesis and genetic risk associations. Linchuang Zhongliuxue
Zazhi. 5:612016.
|
|
11
|
Bao RF, Shu YJ, Hu YP, Wang XA, Zhang F,
Liang HB, Ye YY, Li HF, Xiang SS, Weng H, et al: miR-101 targeting
ZFX suppresses tumor proliferation and metastasis by regulating the
MAPK/Erk and Smad pathways in gallbladder carcinoma. Oncotarget.
7:22339–22354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang F, Chen Y, Duan W, Zhang C, Zhu H and
Ding J: SH-7, a new synthesized shikonin derivative, exerting its
potent antitumor activities as a topoisomerase inhibitor. Int J
Cancer. 119:1184–1193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh F, Gao D, Lebwohl MG and Wei H:
Shikonin modulates cell proliferation by inhibiting epidermal
growth factor receptor signaling in human epidermoid carcinoma
cells. Cancer Lett. 200:115–121. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu D, Qian J, Li W, Feng Q, Pan S and
Zhang S: β-hydroxyisovaleryl-shikonin induces human cervical cancer
cell apoptosis via PI3K/AKT/mTOR signaling. Oncol Lett.
10:3434–3442. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu JP, Liu D, Gu JF, Zhu MM and Cui L:
Shikonin inhibits the cell viability, adhesion, invasion and
migration of the human gastric cancer cell line MGC-803 via the
Toll-like receptor 2/nuclear factor-kappa B pathway. J Pharm
Pharmacol. 67:1143–1155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang H, Zhou P, Huang H, Chen D, Ma N, Cui
QC, Shen S, Dong W, Zhang X, Lian W, et al: Shikonin exerts
antitumor activity via proteasome inhibition and cell death
induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Komi Y, Suzuki Y, Shimamura M, Kajimoto S,
Nakajo S, Masuda M, Shibuya M, Itabe H, Shimokado K, Oettgen P, et
al: Mechanism of inhibition of tumor angiogenesis by
beta-hydroxyisovalerylshikonin. Cancer Sci. 100:269–277. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Xie J, Jiang Z, Wang B, Wang Y and
Hu X: Shikonin and its analogs inhibit cancer cell glycolysis by
targeting tumor pyruvate kinase-M2. Oncogene. 30:4297–4306. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He G, He G, Zhou R, Pi Z, Zhu T, Jiang L
and Xie Y: Enhancement of cisplatin-induced colon cancer cells
apoptosis by shikonin, a natural inducer of ROS in vitro and in
vivo. Biochem Biophys Res Commun. 469:1075–1082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu T, Li R, Zhao H, Deng J, Long Y, Shuai
MT, Li Q, Gu H, Chen YQ and Leng AM: eIF4E promotes tumorigenesis
and modulates chemosensitivity to cisplatin in esophageal squamous
cell carcinoma. Oncotarget. 7:66851–66864. 2016.PubMed/NCBI
|
|
21
|
Jeung YJ, Kim HG, Ahn J, Lee HJ, Lee SB,
Won M, Jung CR, Im JY, Kim BK, Park SK, et al: Shikonin induces
apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1
signaling antagonized by p300. Biochim Biophys Acta.
1863:2584–2593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng
Y, Lv J, Song Z, Li Y, Ji L, et al: Shikonin suppresses tumor
growth and synergizes with gemcitabine in a pancreatic cancer
xenograft model: Involvement of NF-κB signaling pathway. Biochem
Pharmacol. 88:322–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hayashi M: Pharmacological studies of
Shikon and Tooki. (2) Pharmacological effects of the pigment
components, Shikonin and acetylshikonin. Nihon Yakurigaku Zasshi.
73:193–203. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen X, Yang L, Oppenheim JJ and Howard
MZ: Cellular pharmacology studies of shikonin derivatives.
Phytother Res. 16:199–209. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Call JA, Eckhardt SG and Camidge DR:
Targeted manipulation of apoptosis in cancer treatment. Lancet
Oncol. 9:1002–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian
Z, Jiacai H, Jian Z, Wantao C and Chenping Z: Growth inhibition and
induction of apoptosis in human oral squamous cell carcinoma
Tca-8113 cell lines by Shikonin was partly through the inactivation
of NF-kappaB pathway. Phytother Res. 22:407–415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang W, Guo Q, You Q, Zhang K, Yang Y, Yu
J, Liu W, Zhao L, Gu H, Hu Y, et al: Involvement of bax/bcl-2 in
wogonin-induced apoptosis of human hepatoma cell line SMMC-7721.
Anticancer Drugs. 17:797–805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hill MM, Adrain C and Martin SJ: Portrait
of a killer: The mitochondrial apoptosome emerges from the shadows.
Mol Interv. 3:19–26. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nuñez G, Benedict MA, Hu Y and Inohara N:
Caspases: The proteases of the apoptotic pathway. Oncogene.
17:3237–3245. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, An R, Umanah GK, Park H, Nambiar
K, Eacker SM, Kim B, Bao L, Harraz MM, Chang C, et al: A nuclease
that mediates cell death induced by DNA damage and poly(ADP-ribose)
polymerase-1. Science. 354:3542016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jing H, Sun W, Fan J, Zhang Y, Yang J, Jia
J, Li J, Guo J, Luo S and Zheng Y: Shikonin induces apoptosis of
HaCaT cells via the mitochondrial, Erk and Akt pathways. Mol Med
Rep. 13:3009–3016. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang FY, Hu Y, Que ZY, Wang P, Liu YH,
Wang ZH and Xue YX: Shikonin inhibits the migration and invasion of
human glioblastoma cells by targeting phosphorylated β-catenin and
phosphorylated PI3K/Akt: A potential mechanism for the anti-glioma
efficacy of a Traditional Chinese Herbal Medicine. Int J Mol Sci.
16:23823–23848. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tian R, Li Y and Gao M: Shikonin causes
cell-cycle arrest and induces apoptosis by regulating the
EGFR-NF-κB signalling pathway in human epidermoid carcinoma A431
cells. Biosci Rep. 35:352015. View Article : Google Scholar
|
|
34
|
Schroeter H, Boyd CS, Ahmed R, Spencer JP,
Duncan RF, Rice-Evans C and Cadenas E: c-Jun N-terminal kinase
(JNK)-mediated modulation of brain mitochondria function: New
target proteins for JNK signalling in mitochondrion-dependent
apoptosis. Biochem J. 372:359–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakamura Y: Chemoprevention by
isothiocyanates: Molecular basis of apoptosis induction. Forum
Nutr. 61:170–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakanishi M, Shimada M and Niida H:
Genetic instability in cancer cells by impaired cell cycle
checkpoints. Cancer Sci. 97:984–989. 2006. View Article : Google Scholar : PubMed/NCBI
|
